Maintaining Patient, Provider, and Product Continuity at Commercial Launch

A leading orphan and rare disease product manufacturer was approaching a key inflection point in the evolution of its industry-leading intravenously (IV) administered product and faced a near-term need to launch a subcutaneous (SC) formulation to meet an identified unmet patient need and respond to its first competitor product launching across multiple indications and therapy areas. Read more about how they were able to solve the problem in this case study. Download below!